Cochrane · systematic review · CD006887
Risk scoring for the primary prevention of cardiovascular disease
Karmali, KN, Persell, SD, Perel, P, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 7 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
CVD risk scoring for the primary prevention of cardiovascular disease
Population: adults without prevalent cardiovascular disease (primary cardiovascular disease prevention)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
CVD events | RR 1.01 [0.95, 1.08] | 3 studies · 99070 participants | Low Downgraded: risk of bias, imprecision |
Total cholesterol (mmol/L) | no estimate extracted | 12 studies · 20437 participants | Low Downgraded: risk of bias, inconsistency |
Systolic blood pressure (mmHg) | no estimate extracted | 16 studies · 32954 participants | Low Downgraded: risk of bias, inconsistency |
Change in multivariable CVD risk (SD) | no estimate extracted | 9 studies · 9549 participants | Low Downgraded: risk of bias, inconsistency |
Investigator‐defined adverse events | RR 0.72 [0.49, 1.04] | 4 studies · 4630 participants | Low Downgraded: risk of bias, imprecision |
New/intensified lipid‐lowering medication | RR 1.47 [1.15, 1.87] | 11 studies · 14175 participants | Low Downgraded: risk of bias, inconsistency |
New/intensified antihypertensive medication | RR 1.51 [1.08, 2.11] | 8 studies · 13255 participants | Low Downgraded: risk of bias, inconsistency |